Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse
Authors:
- Maria FullerMaria Fuller
- Stephen DuplockSDStephen Duplock
- Christopher TurnerCTChristopher Turner
- Philippa DaveyPDPhilippa Davey
- Doug A. BrooksDoug A. Brooks
- John J. HopwoodJHJohn J. Hopwood
- Peter J. MeiklePeter J. Meikle
- 1 February 2012
- journal article
- Published by Elsevier in Analytical Biochemistry
- Vol. 421 (2) , 759-763
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder—murine Pompe diseaseAutophagy, 2010
- Treatment of infantile Pompe disease with alglucosidase alpha: the UK experienceJournal of Inherited Metabolic Disease, 2010
- Therapeutic Approaches in Glycogen Storage Disease Type II/Pompe DiseaseNeurotherapeutics, 2008
- Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe diseaseMolecular Genetics and Metabolism, 2007
- Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe diseaseLaboratory Investigation, 2006
- Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe DiseaseMolecular Therapy, 2006
- Replacing acid α-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibersMolecular Therapy, 2005
- Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.Journal of Clinical Investigation, 1998
- Glycogenosis type II (acid maltase deficiency)Muscle & Nerve, 1995
- Prenatal diagnosis of Pompe's disease (type ii glycogenosis) in chorionic villus biopsy using maltose as a substratePrenatal Diagnosis, 1992